{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T14:46:44Z","timestamp":1786978004727,"version":"build-2736575974"},"reference-count":32,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2021,7,22]],"date-time":"2021-07-22T00:00:00Z","timestamp":1626912000000},"content-version":"vor","delay-in-days":21,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["EPY 115\/18"],"award-info":[{"award-number":["EPY 115\/18"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J Int AIDS Soc"],"published-print":{"date-parts":[[2021,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>We aimed to assess the effectiveness and tolerability of dolutegravir (DTG), abacavir (ABC) and lamivudine (3TC) administered as branded STR (DTG\/ABC\/3TC) or as two separate pills (DTG and either branded ABC\/3TC [DTG+(ABC\/3TC)b] or generic ABC\/3TC [DTG+(ABC\/3TC)g]).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We included individuals from the multicentre cohort of the Spanish HIV\/AIDS Research Network (CoRIS) who received DTG\/ABC\/3TC, DTG+(ABC\/3TC)b or DTG+(ABC\/3TC)g during 2015 to 2018. We used multivariable logistic regression to compare the proportion of antiretroviral\u2010na\u00efve individuals who achieved viral suppression (VS) (viral load \u226450\u00a0copies\/mL) at 24\u00a0weeks of initiating with DTG+(ABC\/3TC)b or DTG+(ABC\/3TC)g versus DTG\/ABC\/3TC. We also calculated the proportion of virologically suppressed individuals who maintained VS at 24\u00a0weeks after switching from DTG\/ABC\/3TC to DTG+(ABC\/3TC)g.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      During the study period, 829, 68 and 47 treatment\u2010na\u00efve individuals started treatment with DTG\/ABC\/3TC, DTG+(ABC\/3TC)b or DTG+(ABC\/3TC)g respectively. The proportions of individuals who changed their regimens due to side effects during the first 24\u00a0weeks were 3.7%, 4.4% and 6.4% respectively (\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0=\u00a00.646). We did not find significant differences in VS at 24\u00a0weeks among individuals starting with DTG+(ABC\/3TC)b or DTG+(ABC\/3TC)g compared to those initiating with DTG\/ABC\/3TC. Among 177 virologically suppressed individuals who switched from DTG\/ABC\/3TC to DTG+(ABC\/3TC)g, 170 (96.0%) maintained VS at 24\u00a0weeks.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In na\u00efve individuals, the effectiveness and tolerability at 24\u00a0weeks of DTG plus ABC\/3TC administered as two separate pills, either as branded or generic ABC\/3TC, was similar to the STR DTG\/ABC\/3TC. Switching the STR DTG\/ABC\/3TC to its separate components DTG+(ABC\/3TC)g in virologically suppressed individuals did not seem to impair its effectiveness.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/jia2.25758","type":"journal-article","created":{"date-parts":[[2021,7,22]],"date-time":"2021-07-22T03:05:31Z","timestamp":1626923131000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Effectiveness and tolerability of dolutegravir and abacavir\/lamivudine administered as two separate pills compared to their equivalent single\u2010tablet regimen in a multicentre cohort in Spain"],"prefix":"10.1002","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7016-716X","authenticated-orcid":false,"given":"In\u00e9s","family":"Su\u00e1rez\u2010Garc\u00eda","sequence":"first","affiliation":[{"name":"Infectious Diseases Group Department of Internal Medicine Hospital Universitario Infanta Sof\u00eda (FIIB HUIS HHEN) Madrid Spain"},{"name":"Universidad Europea Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bel\u00e9n","family":"Alejos","sequence":"additional","affiliation":[{"name":"National Epidemiology Centre Instituto de Salud Carlos III Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Ruiz\u2010Alguer\u00f3","sequence":"additional","affiliation":[{"name":"National Epidemiology Centre Instituto de Salud Carlos III Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Garc\u00eda Yubero","sequence":"additional","affiliation":[{"name":"Department of Hospital Pharmacy Hospital Universitario Infanta Sof\u00eda (FIIB HUIS HHEN) Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Moreno","sequence":"additional","affiliation":[{"name":"National Epidemiology Centre Instituto de Salud Carlos III Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique","family":"Bernal","sequence":"additional","affiliation":[{"name":"Infectious Diseases Section Hospital General Universitario Reina Sof\u00eda Murcia Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"P\u00e9rez\u2010Is","sequence":"additional","affiliation":[{"name":"FINBA\/ISPA Hospital Universitario Central de Asturias Avil\u00e9s Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuri\u00f1e","family":"Zubero","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases. Hospital Universitario Basurto Bizkaia Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel Alberto","family":"de Z\u00e1rraga Fern\u00e1ndez","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine Hospital San Agust\u00edn Avil\u00e9s Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gloria","family":"Samperiz Abad","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit Hospital Universitario Miguel Servet Zaragoza Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7485-2252","authenticated-orcid":false,"given":"Inma","family":"Jarr\u00edn","sequence":"additional","affiliation":[{"name":"National Epidemiology Centre Instituto de Salud Carlos III Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the Cohort of the Spanish HIV\/AIDS Research Network (CoRIS)","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,7,22]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-146-2-200701160-00003"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)61113-7"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e32834dce6e"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.mlr.0000228021.89490.2a"},{"key":"e_1_2_11_6_1","unstructured":"Ruiz\u2010Alguer\u00f3M Su\u00e1rez\u2010Garc\u00edaI \u00c1lvarez del ArcoD L\u00e1zaroP MorenoS Jarr\u00ednI.Uso de recursos sanitarios y costes asociados al tratamiento antirretroviral de primera l\u00ednea en Espa\u00f1a en la era de los inhibidores de la integrasa Pharm Care.2019;21(2)."},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1086\/497267"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0182007"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-158-2-201301150-00002"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000001467"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1177\/0956462417696215"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0117214"},{"issue":"2","key":"e_1_2_11_13_1","first-page":"466","article-title":"Physicians' opinions on generic antiretroviral drugs and single\u2010tablet regimen de\u2010simplification for the treatment of HIV infection: a multicentre survey in Spain","volume":"75","author":"Suarez\u2010Garcia I","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2013-003028"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/tmi.12297"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000001677"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.12998\/wjcc.v7.i14.1814"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eimc.2016.07.006"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000000199"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0047376"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.12701"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40360-018-0252-z"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eimc.2011.06.002"},{"key":"e_1_2_11_24_1","volume-title":"Coste a\u00f1o de las combinaciones de TAR de inicio recomendadas por GESIDA 2018","author":"Subdirecci\u00f3n General de Farmacia y Productos Sanitarios del Servicio Madrile\u00f1o de Salud","year":"2018"},{"key":"e_1_2_11_25_1","unstructured":"Unidad de vigilancia del VIH y conductas de riesgo.Centro Nacional de Epidemiolog\u00eda \u2013 Instituto de Salud Carlos III\/Plan Nacional sobre el Sida \u2013 Direcci\u00f3n General de Salud P\u00fablica. Estimaci\u00f3n del continuo de atenci\u00f3n del VIH en Espa\u00f1a 2016.2019."},{"key":"e_1_2_11_26_1","unstructured":"Direcci\u00f3n General de Salud P\u00fablica CeI.Informe de Evaluaci\u00f3n Plan Estrat\u00e9gico de Prevenci\u00f3n y Control del VIH e ITS 2013\u20102016.2018."},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200103153441108"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eimc.2013.06.008"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e3283499cd9"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0031591"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1186\/2191-1991-2-16"},{"key":"e_1_2_11_32_1","unstructured":"Sistema de informaci\u00f3n sobre nuevos diagn\u00f3sticos de VIH.Registro nacional de casos de SIDA. Vigilancia epidemiol\u00f3gica del VIH y SIDA en Espa\u00f1a 2019. Actualizaci\u00f3n 30 de junio de 2020.2020."},{"key":"e_1_2_11_33_1","unstructured":"The World Bank.World bank country and lending groups. May 6 2021[cited 2021 May 6]. Available from:https:\/\/datahelpdesk.worldbank.org\/knowledgebase\/articles\/906519\u2010world\u2010bank\u2010country\u2010and\u2010lending\u2010groups"}],"container-title":["Journal of the International AIDS Society"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jia2.25758","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/jia2.25758","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jia2.25758","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T18:29:52Z","timestamp":1693333792000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jia2.25758"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":32,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["10.1002\/jia2.25758"],"URL":"https:\/\/doi.org\/10.1002\/jia2.25758","archive":["Portico"],"relation":{},"ISSN":["1758-2652","1758-2652"],"issn-type":[{"value":"1758-2652","type":"print"},{"value":"1758-2652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"2021-01-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-05-19","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-07-22","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e25758"}}